Navigation Links
Pharmos Corporation Reports 2008 First Quarter Results
Date:5/8/2008

he Company's NanoEmulsion delivery technology, formulated with 3% diclofenac cream, to treat osteoarthritis of the knee commenced in June 2007 targeting 126 patients. Completion of patient recruitment is expected in mid 2008.

General and administrative expenses for the first quarter of 2008 decreased by $1,663,772, or 68%, from $2,460,696 in 2007 to $796,924 in 2008. The decline reflects decreases in virtually every general and administrative expense category. The primary reductions include a $792,730 reduction in payroll and a $674,286 reduction in consultant and professional fees. The decrease in payroll costs reflect the impact of the third and fourth quarter 2007 restructuring plans which have reduced the Company's head count from 51 employees in March 2007 to 14 employees in March 2008. The decrease in consulting and professional fees in 2008 result from non recurring 2007 costs related to contractual payment obligations associated with the retirement of the Company's chief executive officer, higher legal and accounting fees in 2007 and a non recurring recruitment fee of $42,000 in 2007.

Net Operating Loss Shareholder Notice

Under Internal Revenue Code Section 382 rules, a change in ownership can occur whenever there is a shift in ownership by more than 50 percentage points by one or more five-percent shareholders within a three-year period. When a change of ownership is triggered, the Company's net operating losses (NOL) asset may be impaired. The Company believes that substantially all of its Federal NOL generated since 1995 are not impaired, and requests that all investors contact the Company prior to allowing their ownership interest to reach a five-percent level.

About Pharmos Corporation

Pharmos Corporation is a biopharmaceutical company that discovers and develops novel therapeutics to treat a range of diseases of the nervous system, including disorders of the brain-gut axis, with a focus on pain/inflammation and autoim
'/>"/>

SOURCE Pharmos Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pharmos Issues Letter to Shareholders
2. Pharmos Corporation Reports 2007 Third Quarter Results
3. Pharmos Corporation to Present at the 2007 RBC Capital Markets Healthcare Conference
4. Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
5. Pharmos Corporation Announces Board and Management Changes
6. Pharmos Corporation Completes Initial Closing of Private Placement
7. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. BioElectronics Corporation Announces Singapore and Malaysia Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... N.J. , Aug. 31, 2014 Wockhardt ... Drug Discovery program in Anti-Infective research when two of ... coveted Qualified Infectious Disease Product (QIDP) status from U.S. ... to drugs which act against pathogens which have a ... are identified by Centre for Disease Control (a top ...
(Date:8/31/2014)... This is a professional and ... Epoxy Hardener industry in Global and China. ... industry, including definitions, applications and industry chain structure. ... are provided with a focus on history, developments, ... comparison between the international and Chinese situation is ...
(Date:8/29/2014)... are based on electrons, but one of the most ... i.e. circuits based on light (photons) instead of electrons. ... a stream of single photons and control their direction. ... attempts to achieve this control, but now scientists at ... steady stream of photons emitted one at a time ...
(Date:8/29/2014)... PA (PRWEB) August 29, 2014 Pittcon ... Hub MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, have ... on September 5, 2014. JASIS , Asia’s largest ... 3-5, 2014, in Makuhari Messe, Japan. , The ... Tools for Bioanalysis from Single Molecules to Single Cells” ...
Breaking Biology Technology:U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 2Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 3Breakthrough in light sources for new quantum technology 2Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2
... Lentigen Corporation, a biotechnology company specializing in the ... and Expression Therapeutics, a biotechnology company specializing in ... to co-develop novel cell and protein therapies for ... disorder caused by a mutation in the factor ...
... Kendle (Nasdaq: KNDL ) announced today that ... the market closes on Tuesday, Feb. 24, 2009. The Company ... Wednesday, Feb. 25 at 8:30 a.m. Eastern Time. A question ... , To participate in the telephone conference call, interested parties ...
... Feb. 4 On the heels of a strong start ... executives will explain to investors this month where the company ... this year and how it plans to achieve its goal ... by fiscal 2012. Terry Crews, chief financial officer, and Carl ...
Cached Biology Technology:Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement 2Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement 3Kendle Announces Details Regarding Fourth Quarter and Full-Year 2008 Earnings and 2009 Guidance Release, Webcast and Conference Call 2Monsanto Executives to Discuss Company's Growth Drivers, Profit Goals at Investor Conferences in February 2
(Date:9/1/2014)... how the alteration of a single nucleotidethe basic building block of ... intellectual disability. The study appears in The Journal of ... caused by a defect in a gene on the X chromosome ... in 230 women and 1 in 360 men carry a so-called ... of the FMR1 gene is slightly longer than normal. ...
(Date:8/31/2014)... University of Warwick have discovered that ,good, cholesterol is ... substance, methylglyoxal - MG, was found to damage ,good, ... from the body. , Low levels of HDL, ... with increased levels of MG being common in the ... , Supported by funding from the British Heart Foundation ...
(Date:8/31/2014)... busy attacking us, germs go after each other. But ... for the infected microbes: Sometimes viruses actually carry helpful ... its diet or better attack its own hosts. , ... system would robotically destroy anything it recognized as invading ... now revealed that one variety of the bacterial immune ...
Breaking Biology News(10 mins):A nucleotide change could initiate fragile X syndrome 2Sugar substance 'kills' good HDL cholesterol, new research finds 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 3
... & EMS Management Software Provider to Offer Biometrics, ... award-winning,fingerprint biometrics research and development firm, announced today ... Data Systems(R), an,industry leader in the development of ... software and hardware to ZOLL Data,Systems, customers., ...
... 10, 2008 -- The National Institutes of Health (NIH) ... College Assistant Professor of Biology Lara D. Hutson, in ... CMT is the most common inherited neuromuscular disease, ... CMT usually shows dominant inheritance and symptoms generally appear ...
... Human cancer cells divide and conquer. Unless physicians can ... wildly dividing cells will eventually destroy a person,s life. ... an enzyme called telomerase is crucial to cancer,s progress. ... of Georgia,s Franklin College of Arts and Sciences have ...
Cached Biology News:M2SYS Technology Selected by ZOLL Data Systems to Integrate Fingerprint Software 2UGA researchers discover mechanism that explains how cancer enzyme winds up on ends of chromosomes 2
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
... Quality ISO 9001:2000 Certified ... All Precedures Validated, SOP's Training ... Process for All Procedures GLP Documentation Upon ... one stop shopping point for all your ...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
Biology Products: